key: cord-0729403-t8jlihgm
authors: Lan, Shao‐Huan; Lee, Hong‐Zin; Chao, Chien‐Ming; Chang, Shen‐Peng; Lu, Li‐Chin; Lai, Chih‐Cheng
title: Efficacy of melatonin in the treatment of patients with COVID‐19: A systematic review and meta‐analysis of randomized controlled trials
date: 2022-01-23
journal: J Med Virol
DOI: 10.1002/jmv.27595
sha: e4a376f572fe8438287bf12d8645fde0ca8545a2
doc_id: 729403
cord_uid: t8jlihgm

This study investigated the effect of melatonin on clinical outcomes in patients with coronavirus disease 2019 (COVID‐19). We searched PubMed, the Web of Science, the Cochrane Library, Ovid MEDLINE, and Clinicaltrials.gov for randomized controlled trials (RCTs) published before September 11, 2021. Only RCTs that compared the clinical efficacy of melatonin with a placebo in the treatment of patients with COVID‐19 were included. The primary outcome measure was the clinical recovery rate. We included three RCTs in this meta‐analysis. Melatonin 3 mg three times daily was administered in one RCT, and 3 or 6 mg daily before bedtime in the other two trials. Treatment duration was 14 days in two RCTs and 7 days in one trial. The clinical recovery rates were 94.2% (81/86) and 82.4% (70/85) in the melatonin and control groups, respectively. Overall, patients receiving melatonin had a higher clinical recovery rate than did the controls (odds ratio [OR]: 3.67; 95% CI: 1.21−11.12; I (2) = 0%, p = 0.02). The risk of intensive care unit admission was numerically lower in the melatonin group than in the control group (8.3% [6/72] vs. 17.6% [12/68], OR: 0.45; 95% CI: 0.16−1.25; I (2) = 0%, p = 0.13), and the risk of mortality was numerically lower in the melatonin group than in the control group (1.4% [1/72] vs. 4.4% [3/68], OR: 0.32; 95% CI: 0.03−3.18; I (2) = 0%, p = 0.33). In conclusion, melatonin may help improve the clinical outcomes of patients with COVID‐19.

improve the clinical outcomes of hospitalized patients with COVID-19, but it does not provide any survival benefits. 5 Although neutralizing monoclonal antibodies (mAbs) have demonstrated potential in randomized controlled trials (RCTs), current evidence is insufficient for drawing solid conclusions regarding the efficacy of SARS-CoV-2 neutralizing mAbs for patients with COVID-19. 6 Therefore, more effective therapeutic options against this disease are urgently required.

To combat SARS-CoV-2, several artificial-intelligence-based approaches have been developed for the rapid identification of candidate repurposable drugs that target it. 7, 8 Melatonin can serve as an anti-inflammatory, an immunomodulator, and an antioxidant agent, and its efficacy has been demonstrated in multiple experimental disease models and in clinical trials for sepsis, including that triggered by viral infections; it has thus been considered as a potential treatment for COVID-19. 9,10 Furthermore, several clinical studies, including RCTs, have demonstrated the efficacy of melatonin in the treatment of patients with COVID-19. [11] [12] [13] [14] However, most of these RCTs have included only a small sample size. Hence, systematic reviews evaluating the effects of melatonin in larger patient populations are necessary to ascertain its efficacy. Accordingly, we conducted this meta-analysis of RCTs to evaluate melatonin for its efficacy and ability to improve the clinical outcomes of patients with COVID-19.

We searched PubMed, the Web of Science, the Cochrane Library, Ovid MEDLINE, and Clinicaltrials.gov for RCTs published before September 11, 2021. The following search terms were used: "melatonin," "agomelatine," "rozerem," "circadin," "slenyto," "COVID-19," "SARS-CoV-2," "coronavirus," "2019-nCoV," and "corona-virus." We 

The primary outcome measure was the rate of clinical recovery and the secondary outcome measures were the need for intensive care unit (ICU) admission, mortality, and inflammation markers (C-reactive protein [CRP]).

We used the Cochrane risk-of-bias tool 16 to assess the quality of the included RCTs and their associated risk of bias. We performed all statistical analyzes using Review Manager (version 5.3; Nordic Cochrane Center). Heterogeneity was defined when I 2 > 50%. We used a fixed-effects model when the data were homogeneous and used a random-effects model when the data were heterogeneous.

We calculated pooled odds ratios (ORs) and mean differences along with 95% CI for outcome analyses.

The search results yielded a total of 62 studies from the online databases (n = 12 from PubMed; n = 16 from the Web of Science; n = 10 from Ovid MEDLINE; n = 14 from the Cochrane Library, and n = 10 from Clinicaltrials.gov), of which 32 were excluded as duplicates. In addition, we determined 27 studies to be irrelevant after screening their titles and abstracts. Finally, we included three RCTs [12] [13] [14] in this meta-analysis ( Figure 1 , Appendix 1).

Of the three RCTs, only one 13 was a double-blind study (Table 1) . All included RCTs were single-center studies and conducted in Iran. [12] [13] [14] Each of them followed a distinct melatonin regimen. In the trial by 

On the basis of the two RCTs 13,14 that reported the need for ICU admission, we found that the risk of ICU admission was numerically lower in the melatonin group than in the control group (8.3% [6/72] vs. 17.6% [12/68] Regarding inflammation markers, no significant difference was observed between the melatonin group and the control group in terms of the rate of normalization of follow-up CRP levels (OR: 1.14; 

In this meta-analysis, we reviewed three RCTs 12-14 to investigate the additional use of melatonin for the treatment of patients with COVID-19. First, we observed that melatonin was associated with a higher clinical recovery rate than a placebo in the treatment of F I G U R E 1 Flow diagram of study identification and eligibility assessment processes According to our review of the literature, the present study is the first meta-analysis to investigate the usefulness of melatonin in patients with COVID-19 and to demonstrate its potential benefits for improving clinical outcomes. Although this study cannot provide plausible mechanisms, melatonin is a well-known hormone that exhibits anti-inflammatory and antioxidative activity. 18 In addition, studies have demonstrated its ability to protect against acute lung injury or acute respiratory distress syndrome caused by viral and other pathogens. 8, 19, 20 Melatonin is also effective in reducing vessel permeability and anxiety. 19 reported results regarding this factor and it confirmed that oral melatonin could substantially improve the sleep quality of hospitalized patients with COVID-19. 14 The safety of melatonin treatment was not evaluated in this study due to the lack of available data for analysis. Although the safety of melatonin has been demonstrated in clinical practice, [26] [27] [28] further study is still required to assess patient tolerance of melatonin in the treatment of COVID-19. Finally, because the definition of the rate of clinical recovery was not comprehensively described in the original studies, we were unable to make an imprecise statement regarding this outcome.

In conclusion, this meta-analysis revealed that melatonin may help improve the clinical outcomes of patients with COVID-19 and suggested its potential role. However, further large-scale research is required to confirm our findings. | 2105

Clinical efficacy of antiviral agents against coronavirus disease 2019: a systematic review of randomized controlled trials

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis

Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials

SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm

Clinical trial to test the efficacy of melatonin in COVID-19

Therapeutic algorithm for use of melatonin in patients with COVID-19

Melatonin is significantly associated with survival of intubated COVID-19 patients

A pilot study on controlling coronavirus disease 2019 (COVID-19) inflammation using melatonin supplement

Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patients with COVID-19: a randomized, double-blind clinical trial

Melatonin effects on sleep quality and outcomes of COVID-19 patients: an open-label, randomized, controlled trial

Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement

The Cochrane collaboration's tool for assessing risk of bias in randomised trials

Melatonin as adjuvant treatment for coronavirus disease 2019 pneumonia patients requiring hospitalization (MAC-19 PRO): a case series

COVID-19: melatonin as a potential adjuvant treatment

Melatonin for the early treatment of COVID-19: a narrative review of current evidence and possible efficacy

Melatonin in bacterial and viral infections with focus on sepsis: a review. Recent Pat Endocr Metab Immune Drug Discov

The role of melatonin and melatonin receptor agonist in the prevention of sleep disturbances and delirium in intensive care unit -a clinical review

Evaluation of the effect of melatonin in patients with COVID-19-induced pneumonia admitted to the intensive care unit: a structured summary of a study protocol for a randomized controlled trial

A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID trial): a structured summary of a study protocol for a randomised controlled trial

A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial

Evaluation of the efficacy and safety of melatonin in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial

Is melatonin the cornucopia of the 21st century?

Comparative effectiveness and safety of pharmacological and non-pharmacological interventions for insomnia: an overview of reviews

The coronavirus disease 2019 (COVID-19): key emphasis on melatonin safety and therapeutic efficacy

Efficacy of melatonin in the treatment of patients with COVID-19: a systematic review and metaanalysis of randomized controlled trials

APPENDIX 1: SEARCH STRATEGY PubMed search strategy-last searched on

OR (SARS-CoV-2[Title/Abstract])) OR (coronaviru[Title/Abstract])) OR (2019-nCoV[Title/Abstract])) OR (corona-virus

OR (Rozerem[Title/Abstract])) OR (Circadin[Title/Abstract])) OR (Slenyto[Title/Abstract])) OR (melaton*

AND (random*

The authors declare that there are no conflict of interests.

Data sharing is not applicable to this article as no new data were created or analyzed in this study.